Proportion public drug program spending Canada by therapy 2021

This statistic shows the proportion of the total public drug program expenditures in Canada by broad therapeutic category in 2021. In that year, some 25 percent of total drug program spending was dedicated to antineoplastic and immunomodulating agents.

Distribution of total public drug program spending in Canada by therapy in 2021

Characteristic	Share of total public drug spending
Antineoplastic and immunomodulating agents	24.9%
Alimentary tract and metabolism	14.9%
Nervous system	14.4%
Cardiovascular system	9.1%
Sensory organs	6.5%
Respiratory system	5.8%
Blood and blood-forming organs	5.6%
Anti-infectives for systemic use	5%
Musculoskeletal system	2.8%
Genitourinary system and sex hormones	2%
Systemic hormonal preparations (excl. sex hormones and insulins)	1.5%
Various	0.9%
Dermatologicals	0.9%
Anti-parasitic products, insecticides and repellents	0.1%
Unassigned*	1.1%
Non-drug products**	4.3%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

November 2022

More information

Region

Canada

Survey time period

2021

Supplementary notes

Currently, the Northwest Territories and Nunavut do not submit data to NPDUIS.
* This category includes products without an assigned Anatomical Therapeutic Chemical (ATC) code.
** Non-drug products include, but are not limited to, diabetic supplies, wound care, ostomy supplies and pharmaceutical services.

Citation formats